Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011849 (
diabetes
)
277,896
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Alterations in glucose metabolism have been implicated in the cardiovascular complications of
diabetes
. Previous work in this laboratory demonstrated that hearts from diabetic animals have an elevated cytosolic redox ratio (NADH/NAD+) and that this redox imbalance is probably due to elevated polyol pathway flux. We therefore hypothesized that 1) the elevated cytosolic redox ratio of diabetic hearts could result in inhibition of glycolytic enzymes sensitive to the redox state, 2) polyol pathway inhibition could restore the abnormal glucose metabolism of diabetic hearts, and 3) the relative incorporation of mixed substrates into hearts from diabetic animals would demonstrate less glycolytic and more fatty acid oxidation. Hearts from diabetic (BB/W) and nondiabetic control rats were perfused with buffers containing 13C-labeled substrates, and the metabolism of these hearts was analyzed using 13C NMR spectroscopy. Tissue samples were analyzed for metabolite levels using biochemical assay. Compared with controls, diabetic hearts had glyceraldeyde 3-phosphate levels that were four times greater than nondiabetic hearts and exhibited 91% less 13C labeling of lactate and 92% less 13C labeling of glutamate (P < 0.03). Aldose reductase inhibition with zopolrestat restored the metabolite labeling of diabetic hearts. Diabetic hearts perfused with a mixture of substrates used 53% more acetate than nondiabetic control hearts (P < 0.05), and aldose reductase inhibition lowered the acetate utilization of diabetic hearts by 9% (P < 0.05). These data suggest that glycolytic flux in diabetic hearts is inhibited at
glyceraldehyde-3-phosphate dehydrogenase
and that inhibition of the polyol pathway with zopolrestat increases glycolytic flux in these hearts. Furthermore, hearts from diabetic animals showed a marked dependence on fatty acids for substrate utilization compared with nondiabetic controls, consistent with inhibition of the pyruvate dehydrogenase complex in diabetic hearts.
...
PMID:Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. 968 98
The metabolism of [1,3-(13)C]glycerol-1,2,3-tris(methylsuccinate) and glycerol-1,2,3-tris(methyl[2,3-(13)C] succinate) was examined in hepatocytes prepared from hereditarily diabetic Goto-Kakizaki rats. Over 120 min incubation in the presence of one of the two (13)C-labelled esters (2.5 mM), the output of (13)C-enriched glucose averaged 57.1 +/- 18.5 and 54.1 +/- 22.7 nmol per 10(6) cells, when expressed as [1,3-(13)C]glycerol and [2,3-(13)C] succinate equivalent, respectively. In the case of [1,3-(13)C]glycerol-1,2,3-tris(methyl-succinate), the molecules of glucose were symmetrically labelled. In the case of glycerol-1,2,3-tris(methyl[2,3-(13)C] succinate), however, both the single-labelled and double-labelled isotopomers of glucose contained more (13)C atoms in their C(6)-C(5)-C(4) than C(1)-C(2)-C(3) moiety. These findings indicate that glycerol-1,2,3-tris(methylsuccinate), recently proposed as a novel insulinotropic tool for the treatment of non-insulin-dependent
diabetes mellitus
, is efficiently metabolized in hepatocytes from diabetic rats, the high rate of gluconeogenesis coinciding with channelling of D-glyceraldehyde-3-phosphate between
glyceraldehyde-3-phosphate dehydrogenase
and phosphofructoaldolase.
...
PMID:Metabolism of [1,3-(13)C]glycerol-1,2,3-tris(methylsuccinate) and glycerol-1,2,3-tris(methyl[2,3-(13)C]succinate) in hepatocytes from Goto-Kakizaki rats. 1002 53
This study was designed to analyze the sequence and the expression of CRF-BP mRNA in ACTH-secreting pituitary adenomas. Direct sequencing analysis revealed no apparent mutations in the CRF-BP mRNA. Thus, we conclude that mutations in the coding region of the CRF-BP gene are not involved in the pathogenesis of Cushing's disease. However, using a semiquantitative PCR approach coamplifying the house-keeping gene
GAPDH
we detected a reduced expression of CRF-BP mRNA in ACTH-secreting pituitary adenomas when compared with normal pituitaries. We suggest that the decreased CRF-BP gene expression in ACTH-secreting pituitary adenomas is most likely an effect due to high cortisol levels in Cushing patients.
Exp Clin Endocrinol
Diabetes
2000
PMID:Decreased expression of corticotropin-releasing factor-binding protein mRNA in ACTH-secreting pituitary adenomas. 1076 34
Glycation initiated changes in tissue proteins, which are triggered by the Schiff base formation between the sugar carbonyl and the protein -NH2, have been suggested to play an important role in the development of
diabetes
-related pathological changes such as the formation of cataracts. While the initial reaction takes place by the interaction of >C=O of the parent sugars with the -NH2 of proteins, reactive oxygen species (ROS) dependent generation of more reactive dicarbonyl derivatives from the oxidation of sugars also plays a significant role in these changes, altering the structural as well as functional properties of proteins. The purpose of this study was to examine whether the activities of
glyceraldehyde-3-phosphate dehydrogenase
(
GAPDH
), catalase and superoxide dismutase (SOD) could be affected by the high levels of fructose prevalent in diabetic lenses. Incubation of the enzymes with this sugar led to a significant loss of their activities.
GAPDH
was inactivated within a day. This was followed by the inactivation of catalase (3-4 days) and SOD (6 days). The loss of the activities was prevented significantly by incorporation of pyruvate in the incubation mixture. The protective effect is ascribable to its ability to competitively inhibit glycation as well as to its ROS scavenging activity. Hence, it could play a significant role in the maintenance of lens physiology and cataract prevention.
...
PMID:Fructose induced deactivation of antioxidant enzymes: preventive effect of pyruvate. 1082 18
Messenger RNA differential display was applied to screen for the blood glucose-regulated genes in SD rat skeletal muscle. The rat homologue of the mouse prominin was thus identified. Comparing to its mouse and human homologues, fudenine was C-terminal truncated due to a single nucleotide deletion. However, its mitochondrial energy transfer signature peptide PQDLVKKLI remained intact. Fudenine, an 592-amino acid containing, 66-kDa glycoprotein, is a novel plasma membrane protein with four transmembrane segments flanking by two large glycosylated extracellular domains. Although it is devoid of the last transmembrane domain comparing to its homologues, fudenine also locates in cell membrane by transfection of fusion plasmid pFudenine-EGFP into CBRH7919 cell and L-6TG cell. Overexpression of fudenine in CBRH7919 cell line up-regulated the mRNA level of
GAPDH
(3-phosphate glyceraldehyde dehydrogenase), while long-term glucose exposure resulted to reduced
GAPDH
expression. Since high blood glucose level induced the expression of fudenine in skeletal muscle, which in turn up-regulated the expression of
GAPDH
, we propose that fudenine might be a candidate gene for
diabetes mellitus
.
...
PMID:Fudenine, a C-terminal truncated rat homologue of mouse prominin, is blood glucose-regulated and can up-regulate the expression of GAPDH. 1123 53
Oxidant stress, in vivo or in vitro, is known to induce oxidative changes in human red blood cells (RBCs). Our objective was to examine the effect of augmenting RBC glutathione (GSH) synthesis on 1) degenerative protein loss and 2) RBC chemokine- and free radical-scavenging functions in the oxidatively stressed human RBCs by using banked RBCs as a model. Packed RBCs were stored up to 84 days at 1-6 degrees C in Adsol or in the experimental additive solution (Adsol fortified with glutamine, glycine, and N-acetyl-L-cysteine). Supplementing the conventional additive with GSH precursor amino acids improved RBC GSH synthesis and maintenance. The rise in RBC gamma-glutamylcysteine ligase activity was directly proportional to the GSH content and inversely proportional to extracellular homocysteine concentration, methemoglobin formation, and losses of the RBC proteins band 3, band 4.1, band 4.2,
glyceraldehyde-3-phosphate dehydrogenase
, and Duffy antigen (P < 0.01). Reduced loss of Duffy antigen correlated well with a decrease in chemokine RANTES (regulated upon activation, normal T-cell expressed, and secreted) concentration. We conclude that the concomitant loss of GSH and proteins in oxidatively stressed RBCs can compromise RBC scavenging function. Upregulating GSH synthesis can protect RBC scavenging (free radical and chemokine) function. These results have implications not only in a transfusion setting but also in conditions like
diabetes
and sickle cell anemia, in which RBCs are subjected to chronic/acute oxidant stresses.
...
PMID:Glutathione protects chemokine-scavenging and antioxidative defense functions in human RBCs. 1124 4
The effects of benfluorex and two of its metabolites (S 422-1 and S 1475-1) on fatty acid and glucose metabolic fluxes and specific gene expression were studied in hepatocytes isolated from 24-h fasted rats. Both benfluorex and S 422-1 (0.1 or 1 mmol/l) reduced beta-oxidation rates and ketogenesis, whereas S 1475-1 had no effect. At the same concentration, benfluorex and S 422-1 were more efficient in reducing gluconeogenesis from lactate/pyruvate than S 1475-1. Benfluorex inhibited gluconeogenesis at the level of pyruvate carboxylase (45% fall in acetyl-CoA concentration) and of
glyceraldehyde-3-phosphate dehydrogenase
(decrease in ATP/ADP and NAD(+)/NADH ratios). Accordingly, neither benfluorex nor S 422-1 inhibited gluconeogenesis from dihydroxyacetone, but both stimulated gluconeogenesis from glycerol. In hepatocytes cultured in the presence of benfluorex or S 422-1 (10 or 100 micromol/l), the expression of genes encoding enzymes of fatty acid oxidation (carnitine palmitoyltransferase [CPT] I), ketogenesis (hydroxymethylglutaryl-CoA synthase), and gluconeogenesis (glucose-6-phosphatase, PEPCK) was decreased, whereas mRNAs encoding glucokinase and pyruvate kinase were increased. By contrast, Glut-2, acyl-CoA synthetase, and CPT II gene expression was not affected by benfluorex or S 422-1. In conclusion, this work suggests that benfluorex mainly via S 422-1 reduces gluconeogenesis by affecting gene expression and metabolic status of hepatocytes.
Diabetes
2002 Aug
PMID:Effects of benfluorex on fatty acid and glucose metabolism in isolated rat hepatocytes: from metabolic fluxes to gene expression. 1214 46
The sodium-iodide-symporter (NIS) plays a key role in iodination, the first step in the biosynthesis of the thyroid hormones, and is thought to be critically involved in several thyroid disorders associated with altered iodine up-take. To elucidate the pathogenic role of NIS in these diseases a sensitive technique is needed to measure human NIS gene expression. We established a real time RT-PCR for accurate quantification of hNIS mRNA levels based on fluorescence-labelled hybridisation probes in the LightCycler system. Human NIS expression was investigated in primary cultures of human thyrocytes. After optimisation of PCR conditions less than 10 molecules hNIS were detected with high sensitivity, specificity and reproducibility. Under basal conditions NIS expression varied from 83 to 593 copies per 10 6
GAPDH
molecules. Stimulation of thyrocytes with TSH (0.1-10 U/ml) or forskolin (0.1-15 microM) results in a dose- and time-dependent up-regulation of NIS expression reaching a maximum at 10 mU/ml TSH (2211 +/- 761 copies) or 10 microM forskolin (1663 +/- 302 copies) after 24 h. In conclusion, we here established a real-time RT-PCR combining the advantages of rapid thermocycling and online detection of NIS mRNA amplification. The sensitive quantification of human NIS mRNA expression offered by this novel technique may improve analysis of hNIS regulation and measurement of NIS mRNA expression in small biopsies.
Exp Clin Endocrinol
Diabetes
2002 Nov
PMID:Regulation of sodium-iodide-symporter gene expression in human thyrocytes measured by real-time polymerase chain reaction. 1251 50
The sequelae of chronic hyperglycemia in
diabetes
of all phenotypes are divided into microvascular and macrovascular complications. Microvascular disease causes blindness, renal failure, and neuropathy, and
diabetes
-accelerated macrovascular disease causes excessive risk for myocardial infarction, stroke, and lower limb amputation. The link between chronic hyperglycemia and vascular damage has been established by four independent biochemical abnormalities: increased polyol pathway flux, increased formation of advanced glycation end-products (AGEs), activation of protein kinase C (PKC), and increased hexosamine pathway flux. These seemingly unrelated pathways have an underlying common denominator: overproduction of superoxide by the mitochondrial electron transport chain. Mitochondrial reactive oxygen species (ROS) partially inhibit the glycolytic enzymes
glyceraldehyde-3-phosphate dehydrogenase
, which diverts increased substrate flux from glycolysis to pathways of glucose overutilization. Preliminary experimental evidence in vivo suggests that this new paradigm provides a novel basis for research and drug development.
J
Diabetes
Complications
PMID:Pathophysiological mechanisms of diabetic angiopathy. 1262 64
The aim of the present study was to investigate whether diabetic embryopathy may be associated with the inhibition of
glyceraldehyde-3-phosphate dehydrogenase
(
GAPDH
) resulting from an excess of reactive oxygen species (ROS) in the embryo. Recent demonstrations of enhanced ROS production in mitochondria of bovine aortic endothelial cells exposed to high glucose have supported the idea that the pathogenesis of diabetic complications may involve ROS-induced
GAPDH
inhibition. We investigated whether a teratogenic diabetic environment also inhibits embryonic
GAPDH
activity and alters
GAPDH
gene expression and whether antioxidants diminish such
GAPDH
inhibition. In addition, we determined whether the inhibition of
GAPDH
with iodoacetate induces dysmorphogenesis, analogous to that caused by high glucose concentration, and whether antioxidants modulated the putative teratogenic effect of such direct
GAPDH
inhibition. We found that embryos from diabetic rats and embryos cultured in high glucose concentrations showed decreased activity of
GAPDH
(by 40-60%) and severe dysmorphogenesis on gestational days 10.5 and 11.5. GAPDH mRNA was decreased in embryos of diabetic rats compared to control embryos. Supplementing the high-glucose culture with the antioxidant N-acetylcysteine (NAC) increased
GAPDH
activity and diminished embryonic dysmorphogenesis. Embryos cultured with iodoacetate showed both decreased
GAPDH
activity and dysmorphogenesis; supplementing the culture with NAC increased both parameters toward normal values. In conclusion, dysmorphogenesis caused by maternal
diabetes
is correlated with ROS-induced inhibition of
GAPDH
in embryos, which could indicate that inhibition of
GAPDH
plays a causal role in diabetic embryopathy.
Diabetes
2003 May
PMID:Maternal diabetes in vivo and high glucose in vitro diminish GAPDH activity in rat embryos. 1271 56
<< Previous
1
2
3
4
5
6
7
8
9
Next >>